Find the right fit for you - faster
Get tailored insights about working at Agendia in one quick step.
Agendia Snapshot
Agendia was founded on the belief that, as a company, we could improve the outcomes and quality of life for breast cancer patients everywhere by focusing on their needs. Since then, we have successfully commercialized two industry leading tests and have built a product pipeline that will change the landscape for breast cancer treatment. If you are interested in becoming a part of a game-changing global team that is truly making a difference in patient lives and are eager to learn alongside the world’s top researchers, industry leaders and scientific minds then Agendia is the place for you.
From day one, Agendia was founded on the belief we could improve the quality of life for cancer patients everywhere. Today, our genomic tests are achieving this goal with a broad and growing global customer base, including many major hospitals and clinical institutions. Through every step, we continue to stay focused on providing the innovation and dedication that helps patients live better lives.
Here are a few of our company highlights:
2003 — Agendia was founded as a spin-off of the Netherlands Cancer Institute in Amsterdam
2004 — We launched our flagship breast cancer risk of recurrence test, MammaPrint, in Europe
2007 — MammaPrint became the first IVDMIA* to gain 510(k) clearance from the FDA,
and has since received six additional FDA clearances
2007 — We launched MammaPrint in the US
2010 — We introduced our second breast cancer test, BluePrint, a molecular subtyping test
2016 — The landmark MINDACT trial was published, demonstrating the clinical utility of MammaPrint with the highest possible level of evidence (level 1A)
2017 — MammaPrint was recommended in prestigious clinical practice guidelines including ASCO,
the only test of its kind recommended for both lymph node-negative and lymph node-positive patients
2017 — Publication of the STO-3 trial demonstrated that patients with a MammaPrint Late recurrence (20-year) Low Risk result had excellent breast cancer-specific survival, 20 years after diagnosis with little or no hormone therapy
2018 — The MammaPrint and BluePrint Kit attained the CE mark, allowing leading cancer centers across Europe to run these tests in their own labs using their existing next-generation sequencing (NGS) technology†
2018 — MammaPrint and BluePrint were launched to patients and physicians in China
2018 — NCCN guideline inclusion
2020 — Long Term Follow Up MINDACT Data Presented, Company has reached 240 employees
2021 — Company expects to grow to over 300 employees
Here are a few of our company highlights:
2003 — Agendia was founded as a spin-off of the Netherlands Cancer Institute in Amsterdam
2004 — We launched our flagship breast cancer risk of recurrence test, MammaPrint, in Europe
2007 — MammaPrint became the first IVDMIA* to gain 510(k) clearance from the FDA,
and has since received six additional FDA clearances
2007 — We launched MammaPrint in the US
2010 — We introduced our second breast cancer test, BluePrint, a molecular subtyping test
2016 — The landmark MINDACT trial was published, demonstrating the clinical utility of MammaPrint with the highest possible level of evidence (level 1A)
2017 — MammaPrint was recommended in prestigious clinical practice guidelines including ASCO,
the only test of its kind recommended for both lymph node-negative and lymph node-positive patients
2017 — Publication of the STO-3 trial demonstrated that patients with a MammaPrint Late recurrence (20-year) Low Risk result had excellent breast cancer-specific survival, 20 years after diagnosis with little or no hormone therapy
2018 — The MammaPrint and BluePrint Kit attained the CE mark, allowing leading cancer centers across Europe to run these tests in their own labs using their existing next-generation sequencing (NGS) technology†
2018 — MammaPrint and BluePrint were launched to patients and physicians in China
2018 — NCCN guideline inclusion
2020 — Long Term Follow Up MINDACT Data Presented, Company has reached 240 employees
2021 — Company expects to grow to over 300 employees
